Lord, Abbett & Co
NPCE icon

Lord, Abbett & Co’s Neuropace NPCE Stock Holding History

Lord, Abbett & Co’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-400,743
Closed -$4.46M – 563
2025
Q2 		$4.46M Sell
400,743
-65,272
-14% -$816K 0.01% 470
2025
Q1 		$5.73M Buy
+466,015
New +$5.83M 0.02% 443
2022
Q1 		– Sell
-355,972
Closed -$3.59M – 662
2021
Q4 		$3.59M Sell
355,972
-3,449
-1% -$44.8K 0.01% 571
2021
Q3 		$5.7M Buy
359,421
+112,053
+45% +$2.35M 0.01% 582
2021
Q2 		$5.88M Buy
+247,368
New +$5.74M 0.01% 600

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Lord, Abbett & Co's NPCE Position: Q3 2025 in Review

Lord, Abbett & Co sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 400,743 shares — an estimated $4.46M sold.

Lord, Abbett & Co first reported a position in NPCE in Q2 2021 and held it in 5 quarters. The position peaked at $5.88M in Q2 2021. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

  • Lord, Abbett & Co reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
  • Lord, Abbett & Co sold 400,743 Neuropace shares in Q3 2025, an estimated $4.46M.
  • Lord, Abbett & Co first reported a position in Neuropace in Q2 2021 and held it in 5 quarters.
  • Lord, Abbett & Co's Neuropace position peaked at $5.88M in Q2 2021.
  • 80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Lord, Abbett & Co's 13F filing for Q3 2025, filed 13 Nov 2025.